Viking Therapeutics Inc.’s stock soared 90% Tuesday to a record high, after the company announced positive results from a Phase 2 trial of its weight-loss drug VK2735, a GLP-1 receptor agonist that it’s developing in both injectable and oral form as a treatment for obesity and diabetes.
The stock
VKTX,
was on track for its biggest one-day percentage gain since May 31 of 2018 when it rose more than 100%. Volume of 21.6 million shares traded far eclipsed the average of 3.17 million a day for the last 65 days.
The trial met all primary and secondary endpoints, showing statistically significant reductions in body weight at all doses compared with placebo, the company said.
Patients receiving weekly doses of the drug subcutaneously lost up to 14.7% of their body weight from baseline after 13 weeks. The treatment was safe and well-tolerated with 95% of adverse events that were mostly gastrointestinal deemed mild or moderate. Most adverse events occurred early in the trial and patients recovered quickly.
“Up to 88% of patients in VK2735 treatment groups achieved >=10% weight loss, compared with 4% for placebo,” Viking said in a statement.
Viking is planning to meet with the Food and Drug Administration to discuss next steps and hosted a conference call at 8 a.m. Eastern Time with further details.
The news cheered investors looking for a cheaper entry to the weight-loss drug trend than offered by the two leaders in the field, Eli Lilly & Co. Inc.
LLY,
and Denmark’s Novo Nordisk.
NVO,
Viking’s stock closed Monday at $38.48, while Eli Lilly closed at $771.92 and Novo Nordisk’s ADRs closed at $123.49.
Viking’s stock cannot yet be evaluated by traditional forward price-to-earnings or price-to-sales ratios. Consensus estimates among analysts polled by FactSet were negative through 2026, before the market open on Tuesday. Consensus sales estimates for Viking through 2026 were zero for 2024, $1 million for 2025 and $58 million for 2026.
Ten analysts working for brokerage firms polled by FactSet cover Viking and all have buy ratings on the stock. The estimates may be changed significantly over coming days to reflect Tuesday’s news.
Based on Monday’s closing prices, the forward price-to-earnings ratio for Eli Lilly was 57.7. The forward P/E for Novo Nordisk’s Class B American depositary receipts was 35.7.
By comparison, weighted forward P/E ratios were 20.6 for the S&P 500, 19.6 for the S&P 500 healthcare sector, 17.4 for the S&P 500 biotechnology sector industry group and 19.5 for the S&P 500 pharmaceutical industry group, according to FactSet.
Viking’s injectable and oral treatments use the same mechanism as Novo Nordisk’s Wegovy and Ozempic and Lilly’s Mounjaro, mimicking the effects of GLP-1, a gut hormone that can help control blood-sugar levels and reduce appetite. GLP stands for glucagon-like peptide.
The Phase 2 trial involved 176 adults who are obese or overweight, with at least one weight-related comorbid condition. That was increased from an original plan to enroll just 125 patients, due to heightened clinician and patient interests, Chief Executive Brian Lian told analysts on the call.
Statistically significant differences compared with placebo were maintained through the course of the study and weight loss appeared to be progressive and did not show evidence of plateauing, he said.
The company is still expecting data from the trial of an oral version of VK2735 later this quarter, said Lian. Analysts are excited about a pill version of the drug, which would be far easier for patients to manage than the current injectable versions.
Read also: Eli Lilly’s quarterly results top estimates as obesity, diabetes drugs gain insurance coverage
Viking is also developing a treatment for NASH, or nonalcoholic steatohepatitis. NASH is a more severe version of nonalcoholic fatty liver disease, or NAFLD, a range of conditions that occurs when excess fat builds up in liver cells.
NASH is the main reason that patients require liver transplants and there are high hopes for the therapies currently in development.
Lian said the mechanism behind VK2735 “seems to be applicable” for use in NASH, and that may be an additional indication for the treatment.
“I think for now we’re going to direct our resources into obesity, but that would be one obvious indication that could see some some some benefit from the mechanism,” he told analysts, according to a FactSet transcript.
For more, see: Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval
The stock has gained 562% in the last 12 months, while the S&P 500
SPX,
has gained 27%.
The high forward P/E ratios for Elli Lilly and Novo Nordisk reflect analysts’ expectations for continued rapid increases in the companies’ sales and earnings. Here’s a comparison of expected compound annual growth rates (CAGR) for the companies, the S&P 500 and three industry groups through 2025:
| Company | Ticker | Estimated sales CAGR from 2023 through 2025 | Estimated EPS CAGR from 2023 through 2025 |
| Eli Lilly and Co. |
LLY, |
21.8% | 68.6% |
| Novo Nordisk A/S ADR Class B |
NVO, |
20.7% | 22.5% |
| S&P 500 | SPX | 5.4% | 12.1% |
| S&P 500 healthcare sector | 6.4% | 14.1% | |
| S&P 500 biotechnology industry | 4.0% | 9.6% | |
| S&P 500 pharmaceutical industry | 5.8% | 26.7% | |
| Source: FactSet | |||
Additional reporting by Philip van Doorn.